20.84

4.15% +0.83

Aerovate Therapeutics Inc (AVTE)

Overview News Price History Financials Discussions Forecast

Aerovate Therapeutics Inc stock is currently priced at $20.84, with a 24-hour trading volume of 152.64K. It has seen a +4.15% increased in the last 24 hours and a -32.23% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $20.12 pivot point. If it approaches the $21.16 resistance level, significant changes may occur.

Previous Close:

$20.01

Open:

$19.91

24h Volume:

152.64K

Market Cap:

$598.89M

Revenue:

Net Income/Loss:

$-75.52M

P/E Ratio:

-8.0154

EPS:

-2.6

Net Cash Flow:

$-56.92M

1W Performance:

-1.70%

1M Performance:

-32.23%

6M Performance:

+95.86%

1Y Performance:

-1.47%

1D Range:

$19.73

$21.75

52W Range:

$9.41

$32.41

Aerovate Therapeutics Inc Stock (AVTE) Company Profile

Name

Aerovate Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

617-443-2400

Address

200 Berkeley Street, Floor 18, Boston

Employee

Twitter

Next Earnings Date

2024-05-13

Latest SEC Filings

AVTE's Discussions on Twitter

Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-01-23	Initiated	Guggenheim	Buy
Dec-06-22	Upgrade	BTIG Research	Neutral → Buy
Sep-19-22	Resumed	Wedbush	Outperform
Aug-16-22	Downgrade	BTIG Research	Buy → Neutral
Feb-11-22	Initiated	BTIG Research	Buy
Jul-26-21	Initiated	Cowen	Outperform
Jul-26-21	Initiated	Evercore ISI	Outperform
Jul-26-21	Initiated	Jefferies	Buy
Jul-26-21	Initiated	Wedbush	Outperform

View All

Aerovate Therapeutics Inc Stock (AVTE) Latest News

Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday

Benzinga

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

GlobeNewswire Inc.

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

GlobeNewswire Inc.

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

GlobeNewswire Inc.

Aerovate Therapeutics Inc Stock (AVTE) Financials Data

Aerovate Therapeutics Inc (AVTE) Net Income 2024

AVTE net income (TTM) was -$75.52 million for the quarter ending December 31, 2023, a -46.61% decrease year-over-year.

Aerovate Therapeutics Inc (AVTE) Cash Flow 2024

AVTE recorded a free cash flow (TTM) of -$56.92 million for the quarter ending December 31, 2023, a -44.77% decrease year-over-year.

Aerovate Therapeutics Inc (AVTE) Earnings per Share 2024

AVTE earnings per share (TTM) was -$2.88 for the quarter ending December 31, 2023, a -36.18% decline year-over-year.

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.